Tracking H1N1pdm

2017-01-26: Based on the phylogenetic and antigenicity analyses, FutureFlu recommends an A/Montana/04/2016-like vaccine for the 2017-18 flu season, preferably using a recombinant specimen.

2017-04-20: The A/Michigan/45/2015 strain, belonging to the Clade 6B.1, is the recommended vaccine for the 2017-18 flu season. How does it compare to the emerging Clade 6B.2? Analysis using the Antigenic Prediction Model shows that the drift between the two Clades is still within the limits of vaccine efficacy. Analysis

2017-02-12: In their Weekly U.S. Influenza Surveillance Report dated February 10, 2017, CDC stated “The HA gene segment of all influenza A (H1N1)pdm09 viruses analyzed belonged to genetic group 6B.1” (www.cdc.gov/flu/weekly/pdf/External_F1705.pdf).

The A/Montana/04/2016 vaccine recommended by FutureFlu belongs to the same Clade 6B.1. It further supports the analysis by FutureFlu and the need for a new vaccine.

2017-03-01: Strains from Clade 6B.1 continue to dominate H1N1pdm (www.cdc.gov/flu/weekly/pdf/External_F1708.pdf). A/Montana/04/2016 is much more closely associated with Clade 6B.1 genetically than the current vaccine strain A/California/07/2009. Analysis

2017-01-12: Developed a novel Antigenicity Prediction Model of the hemagglutinin inhibition (HI) assay for estimating the avidity of the antibodies generated by a vaccine towards an influenza strain using the proteomic sequences of the strain and the antisera.

2017-03-07: The World Health Organization announced the vaccine for the 2017-18 flu season.

(www.who.int/influenza/vaccines/virus/recommendations/2017_18_north/en/). The A/Michigan/45/2015 strain recommended by WHO shares a 100% proteomic identity with A/Montana/04/2016 recommended by FutureFlu, with eight synonymous nucleotide differences between the two strains. Analysis

What's New?